• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    3/19/24 9:05:53 AM ET
    $ACXP
    $AFIB
    $ELVN
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ACXP alert in real time by email

    Gainers

    • Ontrak (NASDAQ:OTRK) shares rose 173.2% to $0.52 during Tuesday's pre-market session. The company's market cap stands at $14.3 million.
    • Fusion Pharmaceuticals (NASDAQ:FUSN) shares rose 97.46% to $21.01. The company's market cap stands at $1.5 billion.
    • Enveric Biosciences (NASDAQ:ENVB) shares moved upwards by 39.09% to $1.53. The company's market cap stands at $8.2 million.
    • GeneDx Hldgs (NASDAQ:WGS) stock rose 24.22% to $12.0. The market value of their outstanding shares is at $312.6 million.
    • Hoth Therapeutics (NASDAQ:HOTH) shares increased by 22.6% to $1.41. The company's market cap stands at $6.1 million.
    • Enliven Therapeutics (NASDAQ:ELVN) stock rose 17.16% to $14.81. The market value of their outstanding shares is at $612.3 million. The company's, Q4 earnings came out 3 days ago.

    Losers

    • Seelos Therapeutics (NASDAQ:SEEL) stock fell 42.7% to $0.53 during Tuesday's pre-market session. The market value of their outstanding shares is at $7.1 million.
    • Acurx Pharmaceuticals (NASDAQ:ACXP) stock fell 23.56% to $1.98. The market value of their outstanding shares is at $27.2 million. As per the press release, Q4 earnings came out yesterday.
    • Motus GI Hldgs (NASDAQ:MOTS) stock declined by 21.3% to $0.5. As per the press release, Q4 earnings came out yesterday.
    • Acutus Medical (NASDAQ:AFIB) stock fell 19.17% to $0.21. The company's market cap stands at $6.2 million.
    • Streamline Health Solns (NASDAQ:STRM) stock decreased by 15.22% to $0.53. The market value of their outstanding shares is at $31.3 million.
    • TC BioPharm (Holdings) (NASDAQ:TCBP) shares decreased by 9.88% to $1.46. The market value of their outstanding shares is at $3.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACXP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACXP
    $AFIB
    $ELVN
    $ENVB

    CompanyDatePrice TargetRatingAnalyst
    GeneDx Holdings Corp.
    $WGS
    2/9/2026$155.00Equal Weight → Overweight
    Wells Fargo
    GeneDx Holdings Corp.
    $WGS
    10/20/2025$155.00Buy
    Canaccord Genuity
    GeneDx Holdings Corp.
    $WGS
    7/9/2025$110.00Overweight
    Piper Sandler
    Enliven Therapeutics Inc.
    $ELVN
    6/16/2025$37.00Buy
    Goldman
    GeneDx Holdings Corp.
    $WGS
    5/15/2025$88.00Buy
    Guggenheim
    GeneDx Holdings Corp.
    $WGS
    5/9/2025$80.00Hold → Buy
    Jefferies
    Enliven Therapeutics Inc.
    $ELVN
    12/13/2024$42.00Buy
    BTIG Research
    Enliven Therapeutics Inc.
    $ELVN
    9/9/2024$37.00Buy
    H.C. Wainwright
    More analyst ratings

    $ACXP
    $AFIB
    $ELVN
    $ENVB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GeneDx upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded GeneDx from Equal Weight to Overweight and set a new price target of $155.00

    2/9/26 6:58:22 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Canaccord Genuity initiated coverage on GeneDx with a new price target

    Canaccord Genuity initiated coverage of GeneDx with a rating of Buy and set a new price target of $155.00

    10/20/25 8:45:12 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Piper Sandler initiated coverage on GeneDx with a new price target

    Piper Sandler initiated coverage of GeneDx with a rating of Overweight and set a new price target of $110.00

    7/9/25 8:30:02 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $ACXP
    $AFIB
    $ELVN
    $ENVB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF FINANCIAL OFFICER Feeley Kevin converted options into 718 shares and sold $22,248 worth of shares (287 units at $77.52), increasing direct ownership by 5% to 9,599 units (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    3/3/26 4:38:41 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Director Heyman Richard A. sold $32,196 worth of shares (1,230 units at $26.18) (SEC Form 4)

    4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

    2/19/26 6:38:29 PM ET
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF MEDICAL OFFICER Collins Helen Louise exercised 45,000 shares at a strike of $2.48 and sold $1,177,862 worth of shares (45,000 units at $26.17) (SEC Form 4)

    4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

    2/19/26 6:36:48 PM ET
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $AFIB
    $ELVN
    $ENVB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

    Reported positive initial Phase 1b data for ELVN-001 in CML Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026Key data readout, regulatory interactions, and operational catalysts throughout 2026Strong balance sheet with $463 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into the first half of 2029BOULDER, Colo., March 3, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the fourth quarter and full year e

    3/3/26 4:05:00 PM ET
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

    BOULDER, Colo., Feb. 25, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 10:30 a.m. ET.The fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company's website at https://ir.enliventherapeutics.com/. The webcast will be archived for a period of 90 days following the conclusion of the live event.About Enliven TherapeuticsEnliven is a clinic

    2/25/26 4:05:00 PM ET
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GeneDx to Participate in Upcoming Investor Conferences

    GeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that company management will participate in upcoming investor conferences: TD Cowen 46th Annual Health Care Conference Boston, MA Fireside Chat: Monday, March 2 at 1:50 p.m. ET Barclays 28th Annual Global Healthcare Conference Miami Beach, FL Presentation: Wednesday, March 11 at 3:00 p.m. ET Live and archived webcasts of the presentations will be available on the "Events" section of the GeneDx investor relations website at ir.genedx.com/news-events/events. About GeneDx GeneDx's (NASDAQ:WGS) mission is to empower everyone to live their heal

    2/25/26 8:30:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $ACXP
    $AFIB
    $ELVN
    $ENVB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Meister Keith A. bought $3,007,997 worth of shares (50,000 units at $60.16) (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    5/16/25 4:00:06 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Director Meister Keith A. bought $5,600,994 worth of shares (100,000 units at $56.01) (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    5/12/25 7:46:55 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Director Scodari Joseph C bought $25,000 worth of shares (24,631 units at $1.01), increasing direct ownership by 800% to 27,708 units (SEC Form 4)

    4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

    1/8/25 4:32:30 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $AFIB
    $ELVN
    $ENVB
    SEC Filings

    View All

    SEC Form S-8 filed by Enliven Therapeutics Inc.

    S-8 - Enliven Therapeutics, Inc. (0001672619) (Filer)

    3/3/26 5:21:26 PM ET
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Enliven Therapeutics Inc.

    10-K - Enliven Therapeutics, Inc. (0001672619) (Filer)

    3/3/26 4:15:55 PM ET
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enliven Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Enliven Therapeutics, Inc. (0001672619) (Filer)

    3/3/26 4:10:24 PM ET
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $AFIB
    $ELVN
    $ENVB
    Leadership Updates

    Live Leadership Updates

    View All

    Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

    Reported positive initial Phase 1b data for ELVN-001 in CML Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026Key data readout, regulatory interactions, and operational catalysts throughout 2026Strong balance sheet with $463 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into the first half of 2029BOULDER, Colo., March 3, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the fourth quarter and full year e

    3/3/26 4:05:00 PM ET
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development

    Scott Garland, a seasoned biopharma executive with a strong track record of leading successful companies and drug launches, joins Enliven's Board of Directors Building on positive data reported in 2025, Enliven continues to prepare for Phase 3 trial initiation in 2026 and the commercialization of ELVN-001 BOULDER, Colo., Jan. 7, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the appointment of Scott Garland to its Board of Directors and the planned resignation of Andrew Phillips, Ph.D., who has decided to step down, effec

    1/7/26 9:00:00 AM ET
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GeneDx Appoints Dr. Linda Genen as Chief Medical Officer to Accelerate the Future of Genomic-First Care

    Recognized neonatologist and payer-strategy leader joins GeneDx to expand earlier diagnosis and establish genomics as a standard of care across healthcare GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights today announced Linda Genen, MD, MPH as Chief Medical Officer to further strengthen the company's commitment to delivering earlier answers and better outcomes for families through genomic insights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106493899/en/GeneDx Names Dr. Linda Genen, MD, MPH as Chief Medical Officer In her role at GeneDx, Dr. Genen will oversee Medical and Cli

    1/6/26 8:30:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $ACXP
    $AFIB
    $ELVN
    $ENVB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Acutus Medical Inc.

    SC 13D/A - Acutus Medical, Inc. (0001522860) (Subject)

    12/16/24 9:52:56 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Seelos Therapeutics Inc.

    SC 13G/A - SEELOS THERAPEUTICS, INC. (0001017491) (Subject)

    12/4/24 1:29:12 PM ET
    $SEEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

    SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

    11/20/24 9:36:13 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $ACXP
    $AFIB
    $ELVN
    $ENVB
    Financials

    Live finance-specific insights

    View All

    GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026

    Reported fourth quarter 2025 revenues of $121.0 million with 32% year-over-year growth in exome and genome test revenue (42% excluding a one-time 2024 benefit) Accelerated exome and genome volume growth to 34% year-over-year Reported fourth quarter 2025 adjusted gross margin1 of 71% Reported fourth quarter 2025 adjusted net income1 of $4.4 million Reaffirmed full year 2026 guidance of $540 to $555 million in revenue with 33-35% exome and genome growth GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today reported its financial results for t

    2/23/26 6:30:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update

    STATEN ISLAND, N.Y., Feb. 16, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its full year and fourth quarter 2025 financial results on Friday, March 13, 2026 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:Date:                           Friday, March 13, 2026  Time:                     

    2/16/26 8:01:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GeneDx to Report Fourth Quarter 2025 Financial Results on Monday, February 23, 2026

    GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the fourth quarter of 2025 before the market opens on Monday, February 23, 2026. Management will host a conference call that day to discuss fourth quarter 2025 financial and operating results at 8:30 a.m. Eastern Time. Conference Call Details Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the GeneDx investor relations website at https://ir.genedx.com/. About GeneDx GeneDx (NASDAQ:WGS) is the global leader in r

    2/3/26 8:00:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology